よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (95 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
4
105. Fernández-Cuenca F, et al. Spanish Society of Clinical Microbiology and Infectious
Diseases (SEIMC). Reporting antimicrobial susceptibilities and resistance phenotypes in
Acinetobacter spp: a nationwide proficiency study. J Antimicrob Chemother. 2018.
73(3):692-697.
5
6
7
106. Tamma PD, et al. Infectious Diseases Society of America 2024 Guidance on the
Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024.
ciae403.
8
9
10
107. Uechi K, et al. A Modified Carbapenem Inactivation Method, CIMTris, for
Carbapenemase Production in Acinetobacter and Pseudomonas Species. J Clin
Microbiol. 2017. 55(12):3405-3410.
11
12
13
14
108. Khoo BY, et al. Evaluation of NG-Test CARBA 5 version 2, Cepheid Xpert Carba-R, and
carbapenem inactivation methods in comparison to whole-genome sequencing for the
identification of carbapenemases in non-fermenting Gram-negative bacilli. J Clin
Microbiol. 2023. 61(9):e0031623.
15
16
17
109. Betrosian AP, et al. High-dose ampicillin-sulbactam as an alternative treatment of lateonset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis. 2007.
39(1):38-43.
18
19
20
110. Betrosian AP, et al. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as
monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilatorassociated pneumonia. J Infect. 2008. 56(6):432-6.
21
22
111. Khalili H, et al. Meropenem/colistin versus meropenem/ampicillin-sulbactam in the
treatment of carbapenem-resistant pneumonia. J Comp Eff Res. 2018. 7(9):901-911.
23
24
25
26
112. Mosaed R, et al. Interim Study: Comparison Of Safety And Efficacy of Levofloxacin Plus
Colistin Regimen With Levofloxacin Plus High Dose Ampicillin/Sulbactam Infusion In
Treatment of Ventilator-Associated Pneumonia Due To Multi Drug Resistant
Acinetobacter. Iran J Pharm Res. 2018;17(Suppl2):206-213.
27
28
29
113. Shields RK, et al. Navigating Available Treatment Options for Carbapenem-Resistant
Acinetobacter baumannii-calcoaceticus Complex Infections. Clin Infect Dis. 2023.
76(Suppl 2):S179-S193.
30
31
32
33
114. Liu J, et al. Comparative efficacy and safety of combination therapy with high-dose
sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and
extensively drug-resistant Acinetobacter baumannii infections: A systematic review and
network meta-analysis. J Glob Antimicrob Resist. 2021. 24:136-147.
34
35
36
115. Jung SY, et al. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii
pneumonia in critically ill patients: a systemic review and Bayesian network metaanalysis. Crit Care. 2017. 21(1):319.
37
38
39
116. Kengkla K, et al. Comparative efficacy and safety of treatment options for MDR and
XDR Acinetobacter baumannii infections: a systematic review and network metaanalysis. J Antimicrob Chemother. 2018. 73(1):22-32.
40
41
42
117. Karlowsky JA, et al. In Vitro Activity of Sulbactam-Durlobactam against Global Isolates
of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021.
Antimicrob Agents Chemother. 2022. 66(9):e0078122.
43
44
118. Piperaki ET, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an
effective treatment. Clin Microbiol Infect. 2019. 25(8):951-957.
45
46
47
119. Liang CA, et al. Antibiotic strategies and clinical outcomes in critically ill patients with
pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Clin Microbiol
Infect. 2018. 24(8):908.e1-908.e7.
95
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
4
105. Fernández-Cuenca F, et al. Spanish Society of Clinical Microbiology and Infectious
Diseases (SEIMC). Reporting antimicrobial susceptibilities and resistance phenotypes in
Acinetobacter spp: a nationwide proficiency study. J Antimicrob Chemother. 2018.
73(3):692-697.
5
6
7
106. Tamma PD, et al. Infectious Diseases Society of America 2024 Guidance on the
Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024.
ciae403.
8
9
10
107. Uechi K, et al. A Modified Carbapenem Inactivation Method, CIMTris, for
Carbapenemase Production in Acinetobacter and Pseudomonas Species. J Clin
Microbiol. 2017. 55(12):3405-3410.
11
12
13
14
108. Khoo BY, et al. Evaluation of NG-Test CARBA 5 version 2, Cepheid Xpert Carba-R, and
carbapenem inactivation methods in comparison to whole-genome sequencing for the
identification of carbapenemases in non-fermenting Gram-negative bacilli. J Clin
Microbiol. 2023. 61(9):e0031623.
15
16
17
109. Betrosian AP, et al. High-dose ampicillin-sulbactam as an alternative treatment of lateonset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis. 2007.
39(1):38-43.
18
19
20
110. Betrosian AP, et al. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as
monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilatorassociated pneumonia. J Infect. 2008. 56(6):432-6.
21
22
111. Khalili H, et al. Meropenem/colistin versus meropenem/ampicillin-sulbactam in the
treatment of carbapenem-resistant pneumonia. J Comp Eff Res. 2018. 7(9):901-911.
23
24
25
26
112. Mosaed R, et al. Interim Study: Comparison Of Safety And Efficacy of Levofloxacin Plus
Colistin Regimen With Levofloxacin Plus High Dose Ampicillin/Sulbactam Infusion In
Treatment of Ventilator-Associated Pneumonia Due To Multi Drug Resistant
Acinetobacter. Iran J Pharm Res. 2018;17(Suppl2):206-213.
27
28
29
113. Shields RK, et al. Navigating Available Treatment Options for Carbapenem-Resistant
Acinetobacter baumannii-calcoaceticus Complex Infections. Clin Infect Dis. 2023.
76(Suppl 2):S179-S193.
30
31
32
33
114. Liu J, et al. Comparative efficacy and safety of combination therapy with high-dose
sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and
extensively drug-resistant Acinetobacter baumannii infections: A systematic review and
network meta-analysis. J Glob Antimicrob Resist. 2021. 24:136-147.
34
35
36
115. Jung SY, et al. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii
pneumonia in critically ill patients: a systemic review and Bayesian network metaanalysis. Crit Care. 2017. 21(1):319.
37
38
39
116. Kengkla K, et al. Comparative efficacy and safety of treatment options for MDR and
XDR Acinetobacter baumannii infections: a systematic review and network metaanalysis. J Antimicrob Chemother. 2018. 73(1):22-32.
40
41
42
117. Karlowsky JA, et al. In Vitro Activity of Sulbactam-Durlobactam against Global Isolates
of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021.
Antimicrob Agents Chemother. 2022. 66(9):e0078122.
43
44
118. Piperaki ET, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an
effective treatment. Clin Microbiol Infect. 2019. 25(8):951-957.
45
46
47
119. Liang CA, et al. Antibiotic strategies and clinical outcomes in critically ill patients with
pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Clin Microbiol
Infect. 2018. 24(8):908.e1-908.e7.
95